Johnson & Johnson Stock Jumps on Strong Earnings, Higher Outlook
1. JNJ shares surged over 6% after strong Q2 results. 2. Adjusted EPS reached $2.77; sales rose 5.8% to $23.74 billion. 3. Company raised full-year sales forecast to $93.2-$93.6 billion. 4. CEO highlighted growth in pipeline with upcoming drug approvals. 5. Tariff costs could impact JNJ, projected at $400 million this year.